PMID- 32572882
OWN - NLM
STAT- MEDLINE
DCOM- 20210421
LR  - 20210421
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 24
IP  - 11
DP  - 2020 Jun
TI  - STYK1 promotes the malignant progression of laryngeal squamous cell carcinoma 
      through targeting TGF-beta1.
PG  - 6166-6174
LID - 21512 [pii]
LID - 10.26355/eurrev_202006_21512 [doi]
AB  - OBJECTIVE: The aim of this study was to uncover the expression characteristic and 
      biological function of STYK1 in the progression of laryngeal squamous cell 
      carcinoma (LSCC), and to explore the underlying mechanism. PATIENTS AND METHODS: 
      Expression level of STYK1 in 44 paired LSCC and adjacent normal tissues was 
      detected by quantitative real-time polymerase chain reaction (qRT-PCR). The 
      relationship between STYK1 level and clinical parameters of LSCC patients was 
      analyzed. Subsequently, the regulatory effect of STYK1 on the proliferative 
      ability of AMC-HN-8 and Hep-2 cells was evaluated by cell counting kit-8 (CCK-8) 
      assay and colony formation assay. Dual-Luciferase reporter gene assay and rescue 
      experiments were conducted to uncover the role of STYK1/TGF-beta1 axis in regulating 
      the progression of LSCC. RESULTS: STYK1 was significantly up-regulated in LSCC 
      tissues than that of adjacent normal tissues (p<0.05). LSCC patients with high 
      expression level of STYK1 exhibited significantly higher clinical stage and lower 
      survival rate (p<0.05). Knockdown of STYK1 remarkably attenuated viability and 
      clonality in Hep-2 cells, while overexpression of STYK1 achieved the opposite 
      trends in AMC-HN-8 cells (p<0.05). TGF-beta1 was confirmed to be the direct target 
      binding STYK1, whose expression level was negatively regulated by STYK1. TGF-beta1 
      was significantly down-regulated in LSCC tissues  (p<0.05). Meanwhile, its low 
      expression predicted significantly poor prognosis of LSCC patients. In addition, 
      TGF-beta1 was responsible for STYK1-regulated malignant progression of LSCC. 
      CONCLUSIONS: STYK1 is upregulated in LSCC and is closely associated with T stage 
      and poor prognosis. Furthermore, STYK1 promotes the proliferative ability of LSCC 
      cells through targeting TGF-beta1, thus aggravating the malignant progression of 
      LSCC.
FAU - Li, X-L
AU  - Li XL
AD  - Department of Maxillofacial Surgery, Weifang People's Hospital, Weifang, China. 
      592247125@qq.com.
FAU - Huang, Y-Y
AU  - Huang YY
FAU - Yuan, T-J
AU  - Yuan TJ
FAU - Lian, X-P
AU  - Lian XP
FAU - Bi, H-L
AU  - Bi HL
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (TGFB1 protein, human)
RN  - 0 (Transforming Growth Factor beta1)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (STYK1 protein, human)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - *Disease Progression
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Receptor Protein-Tyrosine Kinases/genetics/*metabolism
MH  - Transforming Growth Factor beta1/genetics/*metabolism
EDAT- 2020/06/24 06:00
MHDA- 2021/04/22 06:00
CRDT- 2020/06/24 06:00
PHST- 2020/06/24 06:00 [entrez]
PHST- 2020/06/24 06:00 [pubmed]
PHST- 2021/04/22 06:00 [medline]
AID - 21512 [pii]
AID - 10.26355/eurrev_202006_21512 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2020 Jun;24(11):6166-6174. doi: 
      10.26355/eurrev_202006_21512.